Two Sigma Securities LLC Has $994,000 Position in Medpace Holdings, Inc. $MEDP

Posted by Stanley Muller on Sep 1st, 2026

Two Sigma Securities LLC boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 158.9% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,877 shares of the company’s stock after purchasing an additional 1,152 shares during the period. Two Sigma Securities LLC’s holdings in Medpace were worth $994,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. NewEdge Advisors LLC raised its holdings in shares of Medpace by 22.1% during the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after acquiring an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Medpace by 3.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after purchasing an additional 3,010 shares in the last quarter. Geneos Wealth Management Inc. grew its stake in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in Medpace in the 2nd quarter worth about $296,000. Finally, M&T Bank Corp increased its position in Medpace by 3.4% in the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after purchasing an additional 31 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insider Transactions at Medpace

In other Medpace news, Director Brian T. Carley sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total value of $3,043,150.00. Following the completion of the transaction, the director owned 27,825 shares of the company’s stock, valued at $16,935,129.75. This represents a 15.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO August J. Troendle sold 650 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $620.27, for a total value of $403,175.50. Following the completion of the sale, the chief executive officer owned 539,894 shares of the company’s stock, valued at $334,880,051.38. This represents a 0.12% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 134,471 shares of company stock valued at $82,151,311 in the last ninety days. 20.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on MEDP shares. Barclays set a $600.00 price target on Medpace in a research note on Thursday, July 23rd. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and increased their price objective for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. TD Cowen raised their price objective on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Finally, Robert W. Baird lifted their target price on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Medpace currently has an average rating of “Hold” and a consensus price target of $584.18.

Check Out Our Latest Report on Medpace

Medpace Trading Down 1.1%

Shares of MEDP stock opened at $593.99 on Tuesday. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The firm’s fifty day simple moving average is $568.10 and its 200 day simple moving average is $495.34. The firm has a market capitalization of $16.58 billion, a P/E ratio of 34.82, a price-to-earnings-growth ratio of 2.68 and a beta of 1.15.

Medpace (NASDAQ:MEDP – Get Free Report) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same period in the prior year, the company earned $3.10 EPS. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

About Medpace

(Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.